ARVNARVNHealthcare · Biotechnology

ARVN Stock Forecast: Arvinas, Inc. Price Predictions for 2026-2027

Last close, 13 Nov 2026
$6.82
−0.73% on the day

The 15 Wall Street analysts covering Arvinas, Inc. hold a median 12-month price target of $13 — +90.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 74 of 100 as at 13 Nov 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$446.6M
Ticker Nerd rank
74/ 100
Median analyst target
$13
Analysts covering
15
Revenue$249.7M+1014.7% y/y
Operating income$164.1M
Net income$169.4M
Free cash flow−$48.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+6.4%
1M
−0.3%
YTD
−42.5%
1Y
−32.6%
From 52W high
−50.7%
From 52W low
+6.4%
$6
$14
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ARVN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Arvinas, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 13 Nov 2026
74/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
94
Revisions
85
Issuance
80
Volatility
64
Size
53
Value
47
Growth
44
Momentum
38
Accruals
33

Quality (94): The business earns solid, repeatable profits on what it owns.

Accruals (33): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ARVN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ARVN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20Jan 26Apr 26Jul 26Oct 26ARVNHigh $21Median $13Low $8

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says15 analysts
7 Buy8 Hold0 Sell
Low $8Median $13High $21

The green dot is the last close — the median target sits +90.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
3 Nov 2026HC Wainwright & Co.MaintainsBuy$18 → $13
10 Aug 2026CitigroupMaintainsBuy—
10 Aug 2026CitigroupMaintainsBuy$24 → $21
10 Aug 2026Evercore ISI GroupMaintainsOutperform—
10 Aug 2026Evercore ISI GroupMaintainsOutperform$19 → $14
5 Aug 2026WedbushMaintainsNeutral—
5 Aug 2026WedbushMaintainsNeutral$11 → $12
5 Aug 2026Wells FargoDowngradeEqual-Weight$15 → $11
5 Aug 2026Wells FargoDowngradeEqual-Weight—
4 Aug 2026BTIGReiteratesBuy$18
4 Aug 2026BTIGReiteratesBuy—
3 June 2026Stephens & Co.ReiteratesOverweight$18
3 June 2026Stephens & Co.ReiteratesOverweight—
13 May 2026BarclaysMaintainsOverweight—
13 May 2026BTIGMaintainsBuy—
4 May 2026CitigroupMaintainsBuy—
19 Mar 2026BTIGMaintainsBuy—
19 Mar 2026CitigroupMaintainsBuy—
5 Mar 2026CitigroupMaintainsBuy—
25 Feb 2026Evercore ISI GroupMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

ARVN appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ARVN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 13 Nov 2026, Arvinas, Inc. returned −32.6% against +13.4% for the S&P 500, dividends included.

ARVN vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140Jan 26Apr 26Jul 26Oct 26ARVNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ARVN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
10
Analysts cutting
0
Fundamentals

Arvinas, Inc. (ARVN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
26.5×

Cheaper than 28% of US stocks

Price / sales
1.6×

Cheaper than 56% of US stocks

Price / book
0.9×

Cheaper than 73% of US stocks

EV / EBITDA
4.0×

Cheaper than 54% of US stocks

Growth & margins
Revenue growth (YoY)
−98.8%

Higher than 2% of US stocks

Earnings growth (YoY)
1014.7%

Higher than 98% of US stocks

Gross margin
—
Operating margin
−10.1%

Higher than 24% of US stocks

Net margin
−3.5%

Higher than 25% of US stocks

Returns & dividend
Return on equity
−1.8%

Higher than 42% of US stocks

Return on assets
−2.4%

Higher than 36% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Arvinas, Inc. (ARVN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Arvinas, Inc. has a market value of $446.6M and an enterprise value of −$101.1M.

  • Revenue in the twelve months to 30 June 2026: $316.7M. The latest quarter shrank 98.8% year on year.

  • Net income over the same four quarters: $9.3M, a 2.9% net margin.

  • Diluted earnings per share, trailing twelve months: $0.10.

  • Free cash flow in the twelve months to 30 June 2026: −$208.8M.

  • Shares outstanding: 65.3M.

  • Trailing P/E: 26.5×; forward P/E: −2.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Arvinas, Inc. employs 246 people — $1.3M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Nov 2026

Data provided by Twelve Data

Peers

ARVN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ARVNArvinas, Inc.$446.6M74
AVTXAvalo Therapeutics, Inc.$448.7M38
RLMDRelmada Therapeutics, Inc.$441.6M64
CTMXCytomX Therapeutics, Inc.$441.0M45
PRTAProthena Corp. Plc$439.3M90
CADLCandel Therapeutics, Inc.$454.1M49
IRLAIRulya Therapeutics, Inc.$431.5M31

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Arvinas, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ARVN news & analysis

Arvinas to Present at Jefferies Global Healthcare Conference

GlobeNewsWire · 11 Nov 2026neutral

Arvinas announced that its management will participate in a fireside chat at the Jefferies Global Healthcare Conference on November 18 at 9:00 a.m. GMT (4:00 a.m. EST).

Why it matters — The conference appearance is an opportunity for investors to hear from Arvinas management.

Arvinas to Present Preliminary Clinical Data from Early Monotherapy Dose Escalation Cohorts in the Phase 1 Trial for ARV-393 (Zaloblideg), a PROTAC BCL6 Degrader, at the 2026 American Society of Hematology (ASH®) Annual Meeting

GlobeNewsWire · 4 Nov 2026neutral

Arvinas announced that preliminary Phase 1 data for ARV-393 (zaloblideg) in relapsed/refractory non-Hodgkin lymphoma will be presented at the 2026 ASH Annual Meeting. The presentation will include safety, pharmacokinetics and pharmacodynamics for all patients, plus preliminary efficacy data from patients with T-cell lymphomas.

Why it matters — The presentation will provide an update on the clinical development of Arvinas’s ARV-393 program.

Arvinas, Inc. (ARVN) Q3 2026 Earnings Call Transcript

Seeking Alpha · 3 Nov 2026neutral

Seeking Alpha published a transcript of Arvinas, Inc.’s Q3 2026 earnings call. The provided excerpt contains no further details about the call.

Why it matters — The transcript is a source of information for ARVN watchers, but the excerpt does not describe any company results or announcements.

What Arvinas (ARVN) Said on Its Q3 Earnings Call

MarketBeat · 3 Nov 2026positive

Arvinas outlined upcoming clinical milestones across its oncology and neurology pipeline on its third-quarter 2026 earnings call. The company also reported lower operating expenses and a cash runway projected into the second half of 2028.

Why it matters — The update gives ARVN watchers information on upcoming pipeline milestones and the company’s reported expenses and projected cash runway.

Arvinas, Inc. (ARVN) Reports Q3 Loss, Misses Revenue Estimates

Zacks Investment Research · 3 Nov 2026negative

Arvinas reported a quarterly loss of $0.82 per share, compared with the Zacks Consensus Estimate of a $0.80 loss and a loss of $0.48 per share a year earlier.

Why it matters — The result shows Arvinas’ per-share loss exceeded the consensus estimate and was larger than a year ago.

FAQ

Frequently asked questions about ARVN stock

What is the ARVN stock price forecast for 2026-2027?

The 15 Wall Street analysts covering Arvinas, Inc. have a median 12-month price target of $13, with estimates ranging from $8 to $21. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ARVN stock a buy right now?

Of the 15 analysts covering Arvinas, Inc., 7 rate it a Buy, 8 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Arvinas, Inc. 74 out of 100 across roughly 4,600 US stocks as at 13 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ARVN?

As at 13 Nov 2026, Arvinas, Inc. ranks 74 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (94 of 100).

Will ARVN stock go up?

No one can know that. What the data says: the median 12-month target from 15 analysts implies +90.6% from the last close, and Ticker Nerd's factor model ranks Arvinas, Inc. 74 out of 100 as at 13 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ARVN stock forecast for 2030?

No analyst covering Arvinas, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ARVN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $21 over the next 12 months.

How has ARVN stock performed over the past year?

Arvinas, Inc. returned -32.6% over the 12 months to 13 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Arvinas, Inc. do?

Arvinas, Inc. is a clinical-stage biotechnology company focused on targeted protein degradation.

What is the latest news on ARVN?

The most recent item we track (GlobeNewsWire, 11 Nov 2026): "Arvinas to Present at Jefferies Global Healthcare Conference". Arvinas announced that its management will participate in a fireside chat at the Jefferies Global Healthcare Conference on November 18 at 9:00 a.m. GMT (4:00 a.m. EST).

Company

About Arvinas, Inc.

Arvinas, Inc. is a clinical-stage biotechnology company focused on targeted protein degradation. The company develops therapies designed to harness the body’s natural protein disposal system to selectively degrade disease-causing proteins, using its proprietary PROTAC platform. Its current pipeline includes investigational programs in oncology and neuroscience, with candidates aimed at hormone-driven cancers, mutated cancers, lymphoma, and neurodegenerative disorders. Arvinas also advances collaboration-based programs alongside wholly owned assets, reflecting a business model centered on drug discovery, clinical development, and strategic partnerships. Headquartered in New Haven, Connecticut, Arvinas plays a notable role in the biopharmaceutical market as a developer of next-generation medicines intended to address difficult-to-treat diseases through a differentiated protein-degradation approach.

CEO Dr. Randy Teel Ph.D. · 246 employees · United States · https://www.arvinas.com